AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q3 2015 Earnings Presentation

31 slides from AMAG Pharmaceuticals's earnings presentation, Nov 3, 2015

  1. Slide 1: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including among others, statements regarding future growth drive

  2. Slide 2: 3Q15 Earnings Call Agenda

    3Q15 Earnings Call Agenda Agenda 3Q15 Highlights 3Q15 Commercial Performance and Developments Portfolio Expansion 3Q15 Results and Financial Update 2015 Goals and Closing Remarks Q&A Speakers: Bill Heiden, Chief Executive Officer Frank Thomas, President & Chief Operating Officer Julie Krop, M.D., Ch

  3. Slide 3: 3Q15 Highlights

    Copyright © 2015 AMAG Pharmaceuticals. All Rights Reserved. 3Q15 Highlights

  4. Slide 4: 3Q15 Highlights and Recent Developments

    3Q15 Highlights and Recent Developments Non-GAAP Revenue1 ($ MM) Non-GAAP Adjusted EBITDA1 ($ MM) Non-GAAP Diluted EPS1 ($/share) Sales growth driven by Makena (+36%2), Feraheme (+3%) and the addition of CBR Makena next generation program: subcutaneous auto-injector Initiated start-up activities for

  5. Slide 5: Diversified, Growing Product Portfolio

    Diversified, Growing Product Portfolio Non-GAAP Product Revenues1 ($ MM) $20 $0 $120 $100 $80 $60 $40 3Q15 $103.5 2Q15 $84.7 1Q15 $77.4 4Q14 $49.6 3Q14 Makena2 CBR3,4 Feraheme/Mugard 1See slides 24-26 for reconciliations of GAAP to non-GAAP financial information. 2 Makena acquired in November 2014.

  6. Slide 6: Diversified, Growing Product Portfolio

    Gamay Diversified, Growing Product Portfolio Non-GAAP Product Revenues? (smn $120 $103.5 $100 $247 $80 e774 60 ‘ $49.6 $40 $235 : | 30 3Q14 4Qis 1qis 2Q15 3Q15 Tl Makena? MI Feraheme/Mugard J car“ +See slides 24-26 for reconcillationsof GAAP to non-GAAP financial information. ?Makena acquired in Nov

  7. Slide 7: Makena Demand Continues to Grow

    The only FDA-approved therapy to reduce the risk of recurrent preterm birth, with significant growth potential Makena sales increased 36% in 3Q15 vs. 3Q14 (all volume, no price increase) Gained Medicaid preferred status (i.e. TX, GA) Continued growth across distribution channels Future growth driver

  8. Slide 8: Makena Next Generation Programs

    Makena Next Generation Programs Makena longer-acting formulation Pre Feb 2018 Post Feb 2018 Preservative free More convenient for HCPs More cost effective for insurers In vivo feasibility established Less frequent injections More convenient for patient and HCP Provides opportunity for: Better compli

  9. Slide 9: Makena Subcutaneous Auto-Injector

    Makena Subcutaneous Auto-Injector Targeted Approval and Commercialization Pre-February 2018 Exclusive agreement signed with experienced injector device partner Device technology covered by multiple issued patents Partner’s injector devices are utilized in approved products AMAG provisional patent ap

  10. Slide 10: CBR - Consistent revenues with upside potential

    CBR - Consistent revenues with upside potential: Customers pay: One-time, upfront collection and processing fee Annual storage fee High profit margin on recurring storage stream High customer loyalty; <1% annual attrition rate Acquisition of CBR closed on August 17, 2015 3Q15 decline vs. 3Q14 relate

  11. Slide 11: Hematology / Oncology and Hospital

    Hematology / Oncology and Hospital

  12. Slide 12: Feraheme: Return to Growth in 2H15

    Return to Growth in 2H15 Indicated for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) Key Drivers for Continued Growth: Grow market share in hospital segment Maximize opportunity in hematology/oncology segment Grow overall IV iron market through imp

  13. Slide 13: Growth Opportunities: CKD share and broad IDA indication

    Growth Opportunities: Increase share of ckd market & Gain broad IDA indication ~30% 1 AMAG estimates market opportunity using ~$600/gram. 2 3Q15 IMS Health data annualized. 3 If regulatory approval is received for broad IDA indication. 4 Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Editi

  14. Slide 14: Growth Opportunities: Feraheme IDA trial

    Growth Opportunities Background Submission of sNDA based on two Phase 3 pivotal trials Received Complete Response Letter (CRL) in 1Q14 Request for additional safety data for approval in broader IDA patient population Label revision in March 2015 for current IDA-CKD indication Dosing: 15 minute infus

  15. Slide 15: Product Development Pipeline

    Feraheme IDA - CKD IDA – broad indication Makena Reduction in risk of recurrent pre term birth Outcomes study Single-dose (1mL), preservative-free vial Subcutaneous auto-injector Longer-acting formulation Velo option Severe pre eclampsia CBR Support of small pilot trials conducted by independent inv

  16. Slide 16: Product Development Pipeline

    amag Product Development Pipeline Approves ted Feraheme Anemia IDA-CKD IDA - broad indication Makena Reduction in risk of recurrent pre term birth Outcomes study Single-dose (1mL), preservative-free vial Subcutaneous auto-injector Longer-acting formulation Velo option Maternal Health Severe pre ecla

  17. Slide 17: Building a Diversified Portfolio of Products

    Building a Diversified Portfolio of Products Strong Financial profile, management team & corporate infrastructure Leverage Commercial Expertise with the Acquisition of Products/Companies that Provide Durable Growth Opportunities FUTURE PRODUCT Maternal Health Hematology/Oncology, Nephrology & Hospit

  18. Slide 18: 3Q15 Results & Financial Update

    3Q15 Results & Financial Update

  19. Slide 19: 3Q15 Financial Summary: GAAP to Non-GAAP Comparison

    ($ in millions, except per share data) 3Q15 (GAAP) Adjustments 3Q15 (Non-GAAP) Total revenues $96.2 $7.3 $103.5 Cost of revenue 22.3 (15.5) 6.8 Gross margin 73.9 22.8 96.7 Operating expenses 75.2 (31.4) 43.8 Operating income (loss) / Adjusted EBITDA (1.4) 54.2 52.8 Interest expense and other (33.3)

  20. Slide 20: 2015 Financial Guidance

    2015 Financial Guidance 1 Includes approximately $20 million of non-GAAP revenue related purchase accounting adjustments. 2 See slide 28 for a reconciliation of 2015 updated guidance of non-GAAP adjusted EBITDA and Non-GAAP Net Income/Cash Earnings. ($ in millions) Previous 2015 Guidance Updated 201

  21. Slide 21: 2015 Goals

    2015 Goals Drive sales growth across product portfolio Makena CBR Feraheme & MuGard Adjusted EBITDA margin on product sales in excess of 50% Continue to execute on brand expansion/extension plans Makena next generation development programs, including: Single-dose potential approval Subcutaneous auto

  22. Slide 22: AMAG Pharmaceuticals 3Q15 Financial Results

    AMAG Pharmaceuticals 3Q15 Financial Results November 3, 2015

  23. Slide 23: Appendix

    AMAG Pharmaceuticals Appendix 3Q 2015 Financial Results November 3, 2015

  24. Slide 24: GAAP to Non-GAAP Financials: Three Months Ended September 30

    GAAP to Non-GAAP Financials for the Three Months Ended September 30 AMAG Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations (unaudited, amounts in thousands, except per share data) Three Months Ended Three Months Ended September 30, 2015 Septem

  25. Slide 25: GAAP to Non-GAAP Financials: Nine Months Ended September 30

    GAAP to Non-GAAP Financials for the Nine Months Ended September 30 AMAG Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations (unaudited, amounts in thousands, except per share data) Nine Months Ended Nine Months Ended September 30, 2015 September

  26. Slide 26: GAAP to Non-GAAP Financials: Footnotes

    GAAP to non-GAAP Financials for the Three and Nine Months Ended September 30 7,20 Adding back period write-down of deferred revenue from purchase accounting. 8,21 Eliminate non-cash revenue related to recognition of previously deferred revenue on Takeda agreement. 9,22 Eliminate the following: (i) n

  27. Slide 27: Share Reconciliation

    Share Reconciliation 1 Actual number of shares outstanding at September 30, 2015 is 34.7 million. 2 Since the company reported a loss this period, GAAP diluted shares outstanding is equal to GAAP basic shares outstanding. This information is included for purposes of helping the reader understand the

  28. Slide 28: Adjusted EBITDA and Cash Earnings Reconciliation

    Adjusted EBITDA and Cash Earnings Reconciliation 2015 Updated Guidance ($ in millions) 2015 Updated Guidance GAAP Net income (loss) $15 - $30 CBR deferred revenue $20 Depreciation & amortization of intangible assets $60 Interest expense, net $70 Provision for income taxes $15 EBITDA $180 - $195 Non-

  29. Slide 29: Capitalization

    ($ MM) 3Q15 Cash and cash equivalents $443 Convertible senior notes (2.5%) $200 Term loan facility (4.75%) 350 2023 senior notes (7.875%) 500 Total debt $1,050 Capitalization As of September 30, 2015 ($ MM) Shares outstanding at October 31, 2015 (millions) 34.7 Net operating loss balance at Septembe

  30. Slide 30: AMAG Pharmaceuticals 3Q15 Financial Results

    AMAG Pharmaceuticals 3Q15 Financial Results November 3, 2015

  31. Slide 31: AMAG Pharmaceuticals 3Q15 Financial Results

    AIVIAG Pharmaceuticals 3Q15 Financial|Results November 37 2015) ‘A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES

Amag Pharmaceuticals — Q3 2015 Earnings Presentation on 6ix